Hisamitsu Pharmaceutical Co., Inc. (HTSUF)
Hisamitsu Pharmaceutical Co., Inc.
Tashirodaikan-machi 408
Tosu 841-0017
Japan
81 3 5293 1720
https://www.global.hisamitsu
Sector(es): Healthcare
Industria: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 2,759
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Kazuhide Nakatomi | President, CEO & Director | N/D | N/D | 1972 |
| Mr. Nobuo Tsutsumi | GM of Legal Dept, Prod Environment, Reliability Assurance & Comp Manager, Executive Off and Dir | N/D | N/D | 1964 |
| Kazunori Ito | Executive Officer & GM of Human Resources Department | N/D | N/D | N/D |
| Mr. Kyu Saito | MD, Executive Officer, GM of Global Business & Director | N/D | N/D | 1963 |
| Mr. Shinichi Murayama | Executive Officer of Mgmt. of Internal Audit Division & Domestic Subsidiary Division and Director | N/D | N/D | 1967 |
| Mitsutoshi Tsuruta | Executive Officer & Head of Ethical Division | N/D | N/D | N/D |
| Masaya Okuno | Executive Officer and Head of Sales & Marketing Division, OTC | N/D | N/D | N/D |
| Mr. Koji Takiyama | Executive Officer, GM of President's Office & Director | N/D | N/D | 1971 |
| Katsuhiko Akiyama | Sr. Exe. Officer & GM of MN Commercialization Office | N/D | N/D | N/D |
Descripción
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company provides external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. The company exports its products to Asia, the United States of America, and the European area. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.
Gestión corporativa
La calificación ISS Governance QuickScore de Hisamitsu Pharmaceutical Co., Inc. a partir del 1 de junio de 2024 es 8. Las puntuaciones principales son Auditoría: 1; Junta: 9; Derechos del accionista: 9; Compensación: 1.
